Skip to main content

Cardiac Motion: The Next Log-In Biometric?

BUFFALO, NY — The latest in state-of-the-art innovations using distinct biometric measures for security identification goes straight to the heart—literally.
The Cardiac Scan, described as a "noncontact and continuous heart-based user authentication system," utilizes low-level Doppler radar to identify not just each individual's unique heart dimensions but its function and motion as the security code allowing entry to a system such as a laptop and then continues to monitor the heart to make sure the security hasn't been breached by an unauthorized user[1].
"Cardiac motion is an automatic heart deformation caused by self-excitement of the cardiac muscle, which is unique to each user and is difficult, if not impossible, to counterfeit," explained the authors of a pilot study on the system, to be presented this month at MobiCom 2017, the  Annual International Conference on Mobile Computing and Networking, a conference sponsored by the Association for Computing Machinery.
Heart-based biometrics systems have emerged in the past decade or so in measuring ECG signals, but those systems primarily use electrodes, whereas the Cardiac Scan is a noncontact, remote technology used to assess individual's distinctive heart biometrics.
The system requires approximately 8 seconds to s
can the heart on first use, and, after capturing the dimensions, can continuously monitor usage.
In a pilot study, the developers, with the University of Buffalo's School of Engineering and Applied Sciences, in New York, evaluated the system, including its accuracy, authentication time, usability in complex conditions, and vulnerability.
They found that over four cardiac cycles, the Cardiac Scan achieved a 98.6% rate of balanced accuracy and a 4.42% equal error rate.
"The accuracy is not as high as a professional fingerprint solution, for instance, 10 finger prints in the border check; it is close to daily-life biometric system, such as face recognition," lead author Dr Wenyao Xu, an assistant professor in the department of computer science and engineering, told theheart.org | Medscape Cardiology. Xu and his team have filed a patent on the Cardiac Scan technology.
Some key advantages the Cardiac Scan could have over other biometric tools, such as fingerprints or retinal scans, include that users are automatically authenticated without requiring any contact with the device; users are continuously monitored and do not have to log in or log off when away from their computers.
The system could also be integrated with other existing one-pass user identification techniques to allow for continuous authentication during use.
Xu noted that the system is able to detect a heart's distinctive features and motion regardless of how fast it is beating.
"The heart scan detects the distinctive motion feature oriented by the heart's shape, structure, and function, [and] beat frequency won't change these features," he explained.
It's analogous to facial recognition, where, no matter whether the subject is sitting or walking or running, their face won't change, he said. "We try to find the 'face' in the heart."
The system also can remarkably identify heart features even in a crowd, suggesting the potential to identify people of interest in a setting such as an airport security line.
"The radar can detect heart features without line of sight," Dr Xu said. "It can detect and recognize people with any angles."
Exposure to the signal of the Doppler radar poses no health risks and is an even lower signal strength than a Wi-Fi signal. "The reader is about 5 mW, even less than 1% of the radiation from our smartphones," Dr Xu said.
The researchers plan to miniaturize the scanning system to allow for installation on the corners of computer keyboards.
One potentially important limitation of the system is the role of cardiovascular disease and how that might compromise the ability to authenticate a match, the researchers say. So far, in the pilot stage, the system has been tested using only healthy people, the authors noted.
But just as a heart condition may result in an "access denied" response, it could also feasibly serve as an early warning of potential heart disease, Xu speculated.
"It is an interesting topic to explore," he said. "If someone cannot log in with a heart scan, he may want to see doctor and examine his heart health."

Security Device, Diagnostic Tool?

In commenting on the technology, Dr John A Osborne (Dallas Cardiovascular Center, TX) agreed that the technology is intriguing in its use of the multiple measures of the heart as a unique identifier.
"I think it's very intriguing," he told theheart.org | Medscape Cardiology. "What's interesting is even something simple like an ECG can be like a fingerprint because it's unique for each person, but of course in that case, you have to be hooked up to wires.
"But this is interesting because it goes to the next step of looking at size and geometry and change in the motion of the heart."
He added that the one potential key limitation of heart disease may compromise the system's function as a security device—but could meanwhile provide value as a diagnostic tool.
"The numerous things that could happen to your heart mechanically or electrically could certainly be exploited diagnostically, so a limitation of security could be where the diagnostic usefulness comes in."
The research was supported in part by the US National Science Foundation. Xu and his team have filed a patent on the Cardiac Scan technology. Osborne had no relevant financial relationships.

Comments

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...